Please use this identifier to cite or link to this item:
|Title:||Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil|
|Authors:||Katikireddi, Srinivasa Vittal|
Silva, Thiago Cerqueira
Werneck, Guilherme Loureiro
Ortiz, Renzo Flores
Docherty, Annemarie B.
Ritchie, Lewis D.
Shah, Syed Ahmar
Simpson, Colin R.
Barreto, Mauricio Lima
Oliveira, Vinicius de Araujo
Barral Netto, Manoel
|Affilliation:||Múltipla - Ver em Notas.|
|Abstract:||Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but whether this reflects waning or new SARS-CoV-2 variants—especially delta (B.1.617.2)—is unclear. We investigated the association between time since two doses of ChAdOx1 nCoV-19 vaccine and risk of severe COVID-19 outcomes in Scotland (where delta was dominant), with comparative analyses in Brazil (where delta was uncommon). Methods In this retrospective, population-based cohort study in Brazil and Scotland, we linked national databases from the EAVE II study in Scotland; and the COVID-19 Vaccination Campaign, Acute Respiratory Infection Suspected Cases, and Severe Acute Respiratory Infection/Illness datasets in Brazil) for vaccination, laboratory testing, clinical, and mortality data. We defined cohorts of adults (aged ≥18 years) who received two doses of ChAdOx1 nCoV-19 and compared rates of severe COVID-19 outcomes (ie, COVID-19 hospital admission or death) across fortnightly periods, relative to 2–3 weeks after the second dose. Entry to the Scotland cohort started from May 19, 2021, and entry to the Brazil cohort started from Jan 18, 2021. Follow-up in both cohorts was until Oct 25, 2021. Poisson regression was used to estimate rate ratios (RRs) and vaccine effectiveness, with 95% CIs.|
|Citation:||KATIKIREDDI, Srinivasa Vittal et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. The Lancet, v. 399, p. 25-32, Jan. 1, 2022.|
|Description:||Viviane Boaventura, Thiago Cerqueira-Silva, Renzo Flores-Ortiz, Mauricio L. Barreto, Vinicius de Araujo Oliveira, Manoel Barral-Netto. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.|
(Prof S V Katikireddi PhD, S Amele PhD); Public Health Scotland, Glasgow, UK (Prof S V Katikireddi, Prof C Robertson PhD, B Taylor PhD, J McMenamin MBChB, E Moore PhD); Instituto Gonçalo Moniz, Fiocruz, Bahia, Brazil (T Cerqueira-Silva, R Flores-Ortiz PhD, Prof M L Barreto MD, V d A Oliveira MD, Prof M Barral-Netto MD, Prof V Boaventura MD, Prof M Barral-Netto); Universidade Federal de Bahia, Salvador, Bahia, Brazil (T Cerqueira-Silva, Prof V Boaventura, Prof M L Barreto, Prof M Barral-Netto, V d A Oliveira); Usher Institute, University of Edinburgh, Edinburgh, UK (E Vasileiou PhD, A B Docherty PhD, Prof I Rudan PhD, S A Shah PhD, T Shi PhD, Prof C R Simpson PhD, Prof A Sheikh MD); Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK (Prof C Robertson, J Pan PhD); Departamento de Epidemiologia of Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (Prof G L Werneck PhD); School of Medicine, University of St Andrews, St Andrews, UK (U Agrawal PhD, Prof C McCowan PhD); Academic Primary Care, University of Aberdeen, Aberdeen, UK (Prof L D Ritchie MD); School of Health, Wellington Faculty of Health, Victoria University of Wellington, New Zealand (Prof C R Simpson).
|Appears in Collections:||BA - IGM - Artigos de Periódicos|
Files in This Item:
|Katikireddi_Srinivasa_etal_IGM_COVID-19_2022.pdf||574.04 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.